Several data implicate the immune system in bone lost after estrogen deficiency, however, some of the effects on the immune system of estrogen deficiency or of estrogen receptor (ER) modulation are not well established. In this study, the effect of ER agonists on the immune system in ovariectomized mice is analyzed. Mice were ovariectomized and were administered 178-estradiol (E2), raloxifene (RAL) or genistein (GEN). The effect of a 4-week treatment on bone turnover and on several parameters that reflect the status of the immune system was studied. Results show that ovariectomy provoked both uterine atrophy and thymic hypertrophy. Although RAL corrected thymic hypertrophy, only E2 corrected both. Ovariectomized mice showed increased levels of serum calcium and cathepsin K gene expression and decreased levels of serum alkaline phosphatase (ALP) activity, which suggests that there is a persistent alteration in bone metabolism. Moreover, ovariectomy increased B-cells and CD25+ cells, and decreased the percentages of T-cells and Cbfal gene expression in bone marrow (BM). All ER agonists corrected, although to different degrees, changes induced by the ovariectomy. Furthermore, results showed that it is essential to adjust ER agonist doses to avoid immunosuppression, since all ER agonists decreased BM T-cell levels.
Several data implicate the immune system in bone lost after estrogen deficiency, however, some of the effects on the immune system of estrogen deficiency or of estrogen receptor (ER) modulation are not well established. In this study, the effect of ER agonists on the immune system in ovariectomized mice is analyzed. Mice were ovariectomized and were administered 178-estradiol (E2), raloxifene (RAL) or genistein (GEN). The effect of a 4-week treatment on bone turnover and on several parameters that reflect the status of the immune system was studied. Results show that ovariectomy provoked both uterine atrophy and thymic hypertrophy. Although RAL corrected thymic hypertrophy, only E2 corrected both. Ovariectomized mice showed increased levels of serum calcium and cathepsin K gene expression and decreased levels of serum alkaline phosphatase (ALP) activity, which suggests that there is a persistent alteration in bone metabolism. Moreover, ovariectomy increased B-cells and CD25+ cells, and decreased the percentages of T-cells and Cbfal gene expression in bone marrow (BM). All ER agonists corrected, although to different degrees, changes induced by the ovariectomy. Furthermore, results showed that it is essential to adjust ER agonist doses to avoid immunosuppression, since all ER agonists decreased BM T-cell levels.
Osteoporosis is a major public health problem which is characterized by low bone mass and an increased risk of fracture. It is known that estrogen deficiency is a well-established cause of osteoporosis and a major risk factor for bone loss and fractures, whereas hormone replacement therapy (HRT) prevents, or even reverses, bone loss and reduces fracture risk (l) . However, the recent Women's Health Initiative clinical study (2) shows an increase in the index of cancer appearance and cardiovascular risk in postmenopausal women taking HRT. Therefore, attention has been centered on other therapeutic possibilities with lesser side-effects. Among the products that exert their bone function through estrogen receptors (ERs), it is necessary to underscore the Selective Estrogen Receptor Modulators (SERMs) and phytoestrogens.
Raloxifene is a SERM used to prevent and to treat osteoporosis in postmenopausal women. It has estrogenic effects on cardiovascular and bone systems, while it is antagonistic on breast and uterus tissue, with few recorded side-effects (3) (4) . Phytoestrogens are plant-derived compounds that bind to ERs and have an estrogen-like activity (5) . Due to their potential benefit in the prevention and treatment of cardiovascular and bone problems and menopausal symptoms, and also because of their low toxicity, they are attracting public and medical attention. Those more broadly used in the laboratory are genistein and daidzein (main components of isoflavone pharmaceutical extracts), although genistein is a known enzymatic inhibitor (6) . Consequently, soy isoflavones are considered potential alternatives to HRT.
Evidence that involves the immune system in bone loss have been described. It has been demonstrated that (i) activated T-cel1s are able to stimulate osteoc1astogenesis and bone loss through the RANKL/ RANK pathway, (ii) B-cel1s can generate osteoc1asts, (iii) activated T-cel1s during inflammation stimulate bone loss, and (iv) T-cel1 deficient mice do not lose bone mass after ovariectomy (OYX) (7) (8) (9) . In addition, sex steroids can modulate several aspects ofthe immune system. It has been reported that estrogen deficiency caused by ovariectomy induce thymic hypertrophy (10) , whereas an increased estrogen supply induces an atrophy ofthis gland (II ). Moreover, pregnancy reduces B-cell precursors in the bone marrow (BM) of mice (12) , and estrogen administration selectively reduces B-cell precursors (13) . Nevertheless, the effects of ER agonists on the immune system of estrogen-deprived mice have not been sufficiently studied.
The aim of the present work is to study the effect of ER agonist administration on the immune system of estrogen-deprived mice. Several aspects that reflect the status of the immune system (serum parameters, cel1 function and phenotype, and gene expression) were analyzed, both in spleen as wel1 as in BM, and the effect of ER agonists was evaluated. To do so, ovariectomized mice were administered 17~-estradiol, raloxifene or genistein for four weeks, and cel1 phenotype by means of flow cytometry, cell proliferation as a index of cel1-function, several parameters in serum as total calcium, alkaline phosphatase (ALP) activity, TNF-a, IL-6 and IFN-y, and the expression of specific genes were studied.
MATERIALS AND METHODS

Media and reagents
Recombinant murine macrophage colony stimulating factor (M-CSF) was obtained from PeproTech (London, UK). Monoclonal cm (clone 145-2CII), CD28 (clone: 37.51), Cme-FITC (clone: 145-2Cll), CDllb-FITC (clone: MlnO), CD4-PE (clone: GKI.5), CD8-PE (clone: 53-6.7), RANKL-PE (clone: IK22/5) and Rat-PE negative control (clone: KLH/G2a-l-l) were from e-Bioscience (San Diego, CA). Monoclonal CDI9-FITC (clone: 605), CD25-RPE (Clone: PC61.5.3) and rat-FITC negative control (clone: LO-DNP-16) were from Serotec (Oxford, UK).
Cells were obtained in calcium-and magnesiumfree phosphate-buffered saline (PBS; Gibco, Invitrogen, Carlsbad, CA) and incubated in phenol red-free RPMI-1640 (Gibco) (spleen cells) or in phenol red-free minimum essential medium alpha modified (a-MEM; from Gibco) (BM cells). Media was supplemented with 10% charcoal-stripped, heat inactivated fetal bovine serum (FBS), 2 mM glutamine, 100 IU/ml penicillin G and 100 ug/rnl streptomycin (all from Gibco, Invitrogen). Polymerase chain reaction (PCR) primers and enzymes for retro-transcription (RT) were from Invitrogen. Unless otherwise stated, all other chemical reagents were from Sigma (Sigma-Aldrich Chemical, St. Louis, MO).
Mice and treatments
The ethical committee of our institution approved all animal procedures. Ten-week-old female C57BL/6 mice (Charles River Laboratories, Barcelona, Spain) were either dorsal ovariectomized or falsely operated (SHAM) under general anesthesia by using 150 mg/Kg ofketamine (Merial, Lyon, France) and 5 mg/Kg acepromazine (Calmo Neosan, Pfizer, NY). The animals were kept at 21"C with 12:12-h light-dark cycle and were allowed free access to a pelleted standard mouse laboratory diet containing 0.88% calcium and 0.59% phosphorus (Panlab SL, Barcelona, Spain) and tap water.
The mice were divided into 5 groups of 8 individuals: SHAM, ovariectomized without treatment (OYX), and ovariectomized mice treated with 17p-estradiol (E2), raloxifene (RAL) and genistein (GEN). Starting from the third day after surgery, the mice were subcutaneously injected 5-times per week with 100~I of vehicle (10% DMSO, 90% sesame oil; Sigma Chemicals) to the SHAM and OYX groups, and with 17p-estradiol (0.1 ug/rnouse/ day = 5 ug/Kg/day), raloxifene (20 ug/rnouse/day = I mg/Kg/day) or genistein (0.5 mg/mouse/day = 25 mg/Kg/ day), dissolved in vehicle to the remaining groups. The doses were chosen according to the estrogenic capacity of each compound and the doses frequently used as reported in literature (8, (22) (23) (24) (25) .
Four weeks after beginning the treatment the mice were sacrificed under halothane anesthesia (Fluothane; Zeneca, Macclesfield, UK) by cardiac puncture exsanguination, and the blood, thymus, uterus, spleen and femora were asepticalIy removed. The uterus of each mouse was removed and weighed to confirm the success of ovariectomy and to evaluate the effect of treatment. Spleen and femora were processed immediately. Blood was alIowed to clot and the serum was separated and frozen at -80°C until analysis.
Tissue collection and cell culture
The spleen celIs were isolated by the careful disintegration of spleen with a scalpel in PBS. The BM celIs were isolated from the left femur of animals using centrifugation (8) . Briefly, after the removal of bone adherent soft tissues, femur ends were cut off with scissors and inserted into a 0.6-ml microcentrifuge tube with a hole punctured in the bottom and placed into a 1.5-ml carrier microcentrifuge tube. CelIs were extracted from the bones by centrifugation at 4°C, and resuspended immediately in PBS. Red celIs from spleen and femur suspension celIs were lysed with a solution containing 150 mM NH 4CI, 10 mM KHC0 3 , and 0.1 mM EDTA pH 7.4, centrifuged and washed twice with PBS. An aliquot of these celIs was used for RNA isolation and frozen immediately at -70°C. The remaining celIs were used for cytometric analysis and proliferation assays.
Serum biochemistry
Serum calcium, measured by reaction with 0cresolphthalein, and alkaline phosphatase was assayed using commercial kits (Sigma). Serum total pyridoline crosslinks were measured by a competitive enzymelinked immunosorbent assay (ELISA) folIowing the manufacturer's instructions (Quidel Corporation, San Diego, CA). Serum levels of IL-6, IFN-y and IL-2 were measured by EIA (Diaclone, Besancon, France). Total tartrate resistant acid phosphatase (TRAP) was determined by rapid microplate colorimetric assay. Briefly, p-nitrophenyl phosphate (l0 mM) was used as substrate in a buffer containing 100 mM sodium acetate pH 5.0, 20 mM sodium tartrate and 0.1 % (v/v) Triton X-IOO. Serum samples (20 Ill) were added to 250 III of substrate and incubated at 37°C for 60 min. The reaction was stopped by the addition of75 III of 0.5 M NaOH, and absorbance was read at 405 nm with a microplate reader (Bio-Rad model 550, Richmond, CA).
Cell proliferation and viability analysis
CelI proliferation and viability were evaluated by an XTT-based colorimetric assay (Roche Diagnostics GmbH, Mannheim, Germany), folIowing the manufacturer's instructions. Briefly, 2 x 10 5 spleen or 5 x 10 4 BM celIs in 100 III were placed in 96 welI microtitre plates (Orange Scientific, Braine-I' AlIeud, Belgium), supplemented with glutamine, antibiotics and 10% FBS at 37°C in a humidified atmosphere of 5% CO 2 during 3 days. The stimuli used are indicated in Table II and were added in triplicate. After incubation, 50 III of XTT substrate was added to each welI and incubated under the above-stated conditions. The absorbance of each welI was determined at 450 nm using a microplate reader. Proliferation data in Table II represent the quotient between proliferation of each stimulus (in triplicate) and proliferation of the same celIs in the same culture plate incubated with vehicle (RPMI, a-MEM, ethanol or DMSO).
Flow cytometry
CelIs were labeled with antibodies at the manufacturer's recommended dilutions and conditions. Spleen and BM celIs (1 x 10 6 ) were incubated 30 min on ice with indicated antibodies and then washed and resuspended in PBS containing 1% BSA and 0.1% sodium azide. Non-specific signal was estimated by incubation with rat FITC-and PE-conjugated IgG isotype controls. Labeled celIs were analyzed with an EPICS-XL flow cytometry system (Beckman Coulter). Data were expressed as percentage of positive celIs and as total celIs per femur or spleen.
RNA isolation and semiquantitative RT-PCR
Total RNA was extracted from bone or spleen celIs with Trizol reagent (Invitrogen) folIowing the manufacturer's protocol, and the integrity of the RNA preparations was examined by agarose gel electrophoresis. One microgram of total RNA was reverse transcribed in a 20-IlL-reaction volume into single-stranded cDNA with a first-strand cDNA synthesis kit using an oligo-dT primer (Invitrogen). The subsequent polymerase chain reaction (PCR) was performed with specific primers for each gene with Taq polymerase from Sigma. To ensure equal starting quantities of cDNA for the experiment and to alIow for semiquantification of the PCR products, reverse transcribed RNA samples were amplified with primers specific for glyceraldehyde phosphate dehydrogenase (GAPDH). Amplifications were done using a GeneAmp 9600 thermal cycler (Perkin-Elmer, Norwald, CT, USA), with the temperature cycling set according to the primer length and Tm value. The number ofcycles for each primer pair was determined according to a linear amplification curve established from primary experiments. For each PCR reaction, several samples underwent 12-15 extra cycles ofamplification to guarantee the semiquantification ofthe experiment. Amplified PCR products were separated 
Statistical Analysis
Untransfonned data were analyzed for nonna1ity by the Ko1mogorov-Smimov test. If the data were normally distributed, a two-tailed t test was performed to compare the SHAM group with the OVX/vehic1e group. A one-way (treatment)ANOVAwas performed to ascertain the treatment effect difference between OVX/vehic1e or SHAM and the three different treatments (E2, RAL and GEN) groups at an a = 0.051evel. IftheANOVA test was significant, Dunnett's test (when the variances were assumed to be equal) or Dunnett's T3 test (when the variances were assumed to be unequal) was applied to perform post hoc pairwise comparisons at a = 0.05 level. Levene test was used to test the homogeneity of variance for each dependent variable across all level combinations ofthe between-subject factors. Ifthe data were not normally distributed, a non-parametric Krusta1-Wallis was performed to determine intergroup differences, if any.
The results are presented as means ± SEM. A p value of < 0.05 was considered statistically significant. The entire statistical analysis was carried out using the Statistical Package for Social Sciences (SPSS Inc., Chicago, IL), v. 12.0 for Windows.
RESULTS
Effect of ovariectomy and treatment on physical parameters
The effect of ovariectomy and ER agonist administration on mouse weight and on the relationship between uterus and thymus weights versus mouse weight is shown in Fig. 1 . At the moment of sacrifice there were no weight differences When the effect ofER agonist administration was evaluated, mouse weight was higher in GEN that in OVX mice (p < 0.05). All treatments incremented uterus weight compared with the OVX group (E2: p < 0.0001; RAL: p < 0.0001; and GEN: p < 0.05). Only E2 fully recovered uterus weight, however, since RAL and GEN mice still showed a smaller uterus weight than did SHAM mice (both,p < 0.01). Regarding thymus size, E2 and RAL corrected thymic hypertrophy induced by ovariectomy (p < 0.05) and GEN showed a marked tendency (p = 0.08) ( Fig. 1) .
Effect of ovariectomy and treatment on serum parameters
The effect of ovariectomy and ER agonists on serum parameters is shown in Table I . Four weeks after ovariectomy, serum calcium level was higher in the OVX than in the SHAM group (p < 0.05), while serum ALP activity was lower (p < 0.05). Levels of TRAP, serum pyridinoline crosslinks and assayed cytokines remained unchanged.
When the effect of ER agonist administration was evaluated, there were no significant differences in calcium and ALP levels between treated groups and SHAM mice (Table I) . Finally, treatment did not modify the levels of assayed cytokines with the exception of 1L-2 (Table I ). The level of this cytokine was higher in RAL (p < 0.05 vs. SHAM) and in GEN mice (p < 0.05 vs. OVX, and p < 0.001 vs. SHAM).
Cell proliferation analysis
To evaluate the functionality of spleen and BM cells, in vitro cell proliferation assays were carried out in response to different stimuli (Table II) . Ovariectomy induced an increase in the proliferative response of spleen cells to LPS (p < 0.01). This increase was not observed between treated and 
. Rep resentative flow cytometry dot plots sorted from mouse. Forward and side light scatter plot of unstained cells following red cell lysis from spleen (A) and BM (B) cells. The RI region contains the greatest number oflymphocyte/blast cells in spleen and BM Region 2 in BM includes most ofthe myeloid cells, which are larger cells and have more intracellular granules relative to cells in region Rl . More than 85% ofall cells in myeloid cell gate R2 are positive for monoclonal antibody CD11b recognizing type 3-complement receptor shared by myelomonocytic cells.
SHAM mice (Table II) . Moreover, spleen cells from RAL and GEN mice showed a smaller proliferation in response to PMA than did SHAM mice (p < 0.05). (Table II) . This effect was higher in treated animals compared to SHAM mice (p < 0.05 for E2 and RAL and p < 0.01 for GEN). Proliferation in response to other stimuli, such as IFN -y, CD3+CD28 mAbs, M-CSF or PHA remained unaffected by ovariectomy or treatment. The in vitro cell proliferation rate of BM cells was affected neither for the ovariectomy nor for ER agonists (Table II) .
Finally, O.l -JlM dexamethasone induced apoptosis in all groups
Flow cytometry analysis ofsp leen and BM cells
To examine the effects of ovariectomy and ER agonists on hematopoiesis, cells from spleen and BM were analyzed by flow cytometry. A region in the spleen (Rl) and two regions (Rl and R2) in BM flow cytometry scattering (Fig . 2) were analyzed. Rl contained the greatest number of lymphocytelblast cells, whereas R2 contained most of the myeloid cells . The total number of cells remained unchanged in spleen and BM, although there was a tendency for it to increase by ::::: 20% in the OVX group. All the treatments showed a tendency to reduce total cells per spleen or per femur induced by the ovariectomy, although only E2 showed a significant decrease (p < 0.05) in both organs. Treated mice did not show differences with SHAM mice (results not shown).
In spleen, ovariectomy did not modify cell phenotype (Table III) . E2 decreased total CD3+/ CD4+ and CD 19+ cells compared with OVX mice, while RAL mice also showed a CD3+/CD4+ reduction. In addition, RAL mice showed decreased percentages of CD3+ cells (p < 0.05) while GEN mice showed significant decreases in percentages of all T-cell subtypes (CD3+, CD4+, and CD8+; Table  III) relative to the SHAM group.
OVX caused a more remarkable change in BM cell phenotype. In the lymphoid region of BM (Table IV) , ovariectomy induced a decrease in the percentages of CD3+ cells (p < 0.05) and an increase in CDI9+ cells (p < 0.05). However, only the increase of CD 19+ cells as well as an increase in CD25+ cells (both, p < 0.05) were observed in total cells.
All OVX-treated mice showed both a decrease in the percentages of CD3+ cells relative to SHAM mice (E2,p < 0.001; RAL,p < 0.01, GEN,p < 0.001) and a decrease in total cells per femur compared with OVX and SHAM mice (Table IV ). In addition, E2 and RAL mice showed decreased amounts of total CDI9+ cells (p < 0.01) compared to OVX mice, while only E2 treatment reduced levels of CD25+ cells compared with OVX mice (p < 0.05). Finally, all treated mice groups showed lower levels of RANKL+ cells (p < 0.01) compared with those of OVX mice (Table IV) .
Ovariectomy or treatments affected to the phenotype of cells gated in the myeloid region to a much smaller degree (data not shown). Significant differences in total cells were not observed. Only a decrease in the percentage of CD3+ cells (p < 0.05) in the RAL group compared with the SHAM group, and an increase in the percentage of CD25+ cells (p < 0.05) in the OVX and E2 groups relative to the SHAM mice were observed. Fig. 3 shows mRNA expression levels assessed by semiquantitative RT-PCR in RNA samples extracted from BM cells. After 4 weeks of treatment, a high level of cathepsin K expression persisted in the OVX and GEN groups compared with the SHAM mice, but not in E2 and RAL mice. Unexpectedly, it was observed that ovariectomy induced a lower expression level of Cbfal. Finally, ovariectomy or ER agonists did not affect the expression of other evaluated genes such as RANKL and OPG (Fig. 3) or CD25, TRAP, osteocalcin, or IFN-y (data not shown).
Gene expression
DISCUSSION
The major point of the present study is that modulation of ER by the agonists tested (17[3estradiol, raloxifene and genistein) corrects in similar direction, but with different levels of efficacy, the effects that estrogen deficiency induces on the immune system. Data also point towards the necessity of adjusting ER agonist doses to avoid not only agonistic effects on the uterus, but also immunosuppression like the decreased levels of the T-cells described in this work.
An altered bone metabolism persisted four weeks after ovariectomy, as shown by increased levels of serum calcium and cathepsin K expression in BM and decreased serum levels of ALP in OVX mice (Table I and Fig. 3) . Changes in the levels of other markers, however, have not been detected (Table I) , which implies that bone turnover tends to stabilize. Ovariectomy accelerates bone turnover, causing an increase in bone resorption as well as in bone formation. In the mouse, these markers (including total and bone-specific ALP) peak the first days post-surgery and then decline. Subsequently, by 4-5 weeks post-surgery, the levels had normalized almost completely (14) (15) (16) . The decreased levels of ALP, a marker of bone formation (17) , imply that bone formation is impaired in OVX mice. In accordance with this, there was a decreased expression of osteoblastic transcription factor Cbfal in BM of OVX mice. The data suggest, therefore, that 4 weeks after ovariectomy a decreased level of bone formation and a smaller osteogenic potential exist in OVX mice. In agreement with our data, decreases in serum ALP and in pre-osteoblastic cells in estrogen deficiency (18) , and a down-regulation of ALP and Cbfal gene expression by ovariectomy and an upregulation by estrogens in BM mesenchymal stem cells of mice (19) , have been described.
Levels ofall markers ofbone metabolism returned to normality after ER agonist treatment, except for cathepsin K, a protease that plays an essential role in osteoclast-mediated degradation of the organic matrix of bone, whose expression normalized only by E2 and RAL. Changes in rat OPG, RANKL and bone sialoprotein gene expression the first and second weeks, but not the fourth week, after ovariectomy have been described (20) . This indicates that, as for bone biochemical markers, changes in gene expression come about in the first weeks after ovariectomy.
In bone, the binding of RANKL to RANK on pre-osteoclasts, together with M-CSF, is necessary and sufficient to initiate osteoclastogenesis (21) . The present data show that ovariectomy tends to increase RANKL+ cells in BM (p = 0.13). This increase agrees with a previous study which demonstrates that estrogen deficiency increases RANKL expression in BM (18) . The present study shows that all ER agonists tested down-regulate BM RANKL+ cells induced by ovariectomy (Table IV) , similar to what occurs in BM of HRT-treated postmenopausal women (18) .
Estrogenic deficiency induced by ovariectomy caused dramatic uterine atrophy (Fig. 1 ). Only E2 totally recovered uterus weight after 4 weeks of treatment. Although RAL have antagonistic activity in uterine tissue (22) , Fig. 1 shows that, both RAL as well as GEN display agonistic properties in this organ. It seems, however, that when RAL is administered to intact females, the uterus suffers atrophy, demonstrating its antagonistic properties (23) . Our results contrast with those of previous studies in which doses of GEN (24) or E2 (25) similar to those used in the present research, prevented trabecular bone loss without hypertrophic effects on the uterus. In agreement with our data, RAL have shown agonistic effects on the uterus of ovariectomized animals (22) . Moreover, the intake of large amounts of phytoestrogens causing impaired reproductive function has been described (26) . Therefore, regarding uterine physiology, our results show that the behaviour of GEN is similar to that RAL, and that to avoid adverse effects on the uterus, ER agonist doses should be adjusted for use in humans.
Sex steroids are involved in lymphopoiesis. Whereas B lymphopoiesis is suppressed during pregnancy (12) , it is : upregulated in estrogen deficiency (27) . Additionally estrogens are negative regulators of lymphopoiesis (13) . In the present study, estrogen deficiency induced a selective increase in BM B-and CD25+ cells. These results agree with those of a previous study in which a selective increase in B-cells after estrogen deficiency is demonstrated (27) . It is possible that appropriate attention is not given to B-cell increases after ovariectomy, and that these cells participate actively in bone loss under conditions of estrogen deficiency. Bone resorption following estrogen deficiency is caused primarily by increased numbers of boneresorbing osteoclasts derived from myelopoietic lineage, although, confirming previous results (27) , the present study found no increase of myeloid cells (CD II b+) after ovariectomy. Considerable data, however, support the essential role of B-cells in bone loss. For example, the existence ofbipotent B/ macrophage cells (28) , osteoclasts formed from early B-cells (7), pre-B-cells expressing RANKL (29) and multiple myeloma plasma cells expressing RANKL implicated in the formation of osteoclast in vivo (30) , have been reported. In accordance with previous data (13, 27) , where it was demonstrated that E2 decreased B-cell lymphopoiesis, our data show that all ER agonists tested show the same tendency to decrease B-cells, although only the results of E2 and RAL reached statistical significance. In spleen, like BM, estradiol also decreased B-cellieveis.
Ovariectomy induced an increase in BM CD25+ cell levels. Increases of CD25+ and CD69+ T-cells in BM ofOVX mice (31) and ofCD25+ and HLA-DR+ T-cells in postmenopausal women (32), have been described. All of these are activation markers that seem to be in the basis of ovariectomy-induced bone loss. The increase of CD25 marker (IL-2 receptor alpha chain), that is expressed on activated T, B-cells and macrophages, has not been well explained, particularly if IL-2 levels do not change with ovariectomy (Table I) . Only estradiol was able to reduce the number of CD25+ cells, although raloxifene also showed the same tendency.
Estrogen receptors have been demonstrated in the thymus (33) , suggesting that ER agonists can modulate T-cell lymphopoiesis. In fact, it has been reported that ovariectomy induces thymic hypertrophy (10), whereas estrogen administration induces thymic atrophy (10) (11) , as occurs during normal pregnancy when high sex steroid levels exist (34) . Nevertheless, the effect of estrogen deficiency or ER agonists on the T-cell content of lymphoid tissues, particularly in BM, remains unclear. The present results demonstrate that ovariectomy induces thymic hypertrophy (Fig. 1) , and that ER agonists tend to correct it, although only the results ofE2 and RAL reached statistical significance. In the present study, ovariectomy decreased the percentage of Tcells, but not total T-cell levels using a specific CD3 mAb. Results of the study support previous data from other authors which describe ovariectomy as either having no effect on, or reducing BM T-cell levels (10, 27, 35) . An increase in BM T-cell content, however, has been described after OVX (8, 36) . The role of T-cells in bone loss after ovariectomy is evident since T-cell deficient mice do not lose bone after ovariectomy (8) . Therefore, additional studies are needed to establish the effect of estrogen deficiency on T-cells.
This study shows that the modulation of ER with all the agonists tested, induced a down-regulation of BM CD3+ and spleen CD3+/CD4+ T-cell content (Tables III and IV) . Cell functionality, however, was not affected by ovariectomy or by ER agonists. Cell functionality was evaluated by means of cell proliferation in vitro assays; therefore, it is not possible to conclude that other cellular functions are not affected. In fact, estrogen inhibits NK-cellmediated cytotoxicity and granulocyte-mediated inflammation, and ER agonists impair T-cell functionality (37) (38) . The increment in serum IL-2 levels induced by some agonists, especially by genistein, may be indicative of this T-cell function impairment, since inhibition of IL-2/IL-2R complex endocytosis in T-cells by genistein has been described (39) . Additionally, ER agonist administration increased dexamethasone-induced apoptosis (Table II) . All these data, together with data concerning agonistic properties ofER agonists in the uterus of ovariectomized mice (see Results), point towards the need of adjusting the dose of compounds prescribed as alternatives to HRT to avoid possible immunosuppressant effects. Moreover, it has recently been described that raloxifene and tamoxifen impair dendritic cell differentiation and activation (40) .
In summary, 4 weeks after ovariectomy, when bone metabolism tends to normalize, several changes in the immune system persist. These changes mainly affect the phenotype of BM cells, although other compartments of the immune system are altered as well. Modulation of ER by the agonists tested tends to improve all ovariectomy-induced changes in immune as well as in bone systems. Except for minor aspects, all ER agonists acted in the same direction, although with different force and probably with different side-effects as regards immune system functionality and immunosuppression.
